Gufic Biosciences Ltd
Ticker: GUFICBIO
Decent
68/100
☆ Add to Watchlist
Investing Reference
Price
363.50
Market Cap
3645.27
Debt/Equity
0.5593
ROE %
12.290
PB
6.0646
Promoter %
72.507
Pledge %
0.000
1Y Rev Growth %
1.804
5Y Rev Growth %
NP Margin %
8.460
NP Margin 5Y Avg %
Trading Reference
1M Return %
-1.070
6M Return %
6.770
1Y Return %
-10.841
% Away 52W High
38.721
% Away 52W Low
21.653
Daily Volume
53071
Investment Verdict
Hold
Score 62/100 · Position size: 30%
Fundamentals are OK but not compelling. Maintain current position; avoid fresh adds.
Trading Verdict
Avoid
Score 23/100 · Position size: 0%
Momentum weak or trend adverse. Avoid trading at this point.
Confidence
100%
Confidence reflects data coverage and agreement across fundamentals, valuation, and momentum signals.
AI Probability Statement
Probability Statement
Gufic Biosciences Ltd is currently trading near a strong support level, with recent price action showing increased buying volume. If it breaks above the resistance level, it could see a significant upside. However, if it fails to hold the support, there is a risk of a downside movement.
Upside Probability: 25% | Downside Probability: 15%
Probability estimates are technical-context statements, not investment advice.
More Options
M
MPS Ltd
MPS Ltd shows potential but faces challenges in growth consistency and market competition.
View details
T
TCNS Clothing Co Ltd
TCNS Clothing Co Ltd shows potential in a growing sector, but faces challenges in execution and valuation.
View details
P
Protean eGov Technologies Ltd
Protean eGov Technologies Ltd shows potential in a growing sector, but faces challenges in profitability and execution risks.
View details
P
Pondy Oxides and Chemicals Ltd
Pondy Oxides and Chemicals Ltd shows potential in a growing sector, but faces challenges in growth consistency and market sentiment.
View details
N
Nalwa Sons Investments Ltd
Nalwa Sons Investments Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
M
Madhya Bharat Agro Products Ltd
Madhya Bharat Agro Products Ltd shows potential in a growing sector, but faces challenges in consistency and governance.
View details
S
Standard Glass Lining Technology Ltd
The company operates in a promising sector but faces challenges in profitability and market sentiment. Caution is advised.
View details
F
Fusion Finance Ltd
Fusion Finance Ltd shows potential for growth but faces challenges in profitability and valuation metrics. Caution is advised.
View details
M
Mangalore Chemicals and Fertilisers Ltd
The stock presents several risks with inconsistent growth and profitability metrics, making it a risky investment.
View details
J
Jindal Worldwide Ltd
Jindal Worldwide Ltd shows potential but faces challenges in growth consistency and valuation metrics. Caution is advised.
View details
C
Cyient DLM Ltd
Cyient DLM Ltd shows potential for growth but faces challenges in profitability and valuation metrics. Caution is advised.
View details
D
Ddev Plastiks Industries Ltd
Ddev Plastiks Industries Ltd shows potential in a growing sector, but faces challenges in profitability and execution risks.
View details
I
IndoStar Capital Finance Ltd
IndoStar Capital Finance Ltd shows potential but faces challenges in growth consistency and market competition.
View details
T
TechNVision Ventures Ltd
TechNVision Ventures Ltd shows potential but faces significant challenges in growth and profitability metrics.
View details
O
Orchid Pharma Ltd
Orchid Pharma Ltd presents several risks with inconsistent growth and high debt levels, making it a risky investment.
View details
S
Sagar Cements Ltd
Sagar Cements Ltd shows potential for growth in a vital sector, but faces challenges in profitability and execution risks.
View details
Business Overview
Gufic Biosciences Ltd is a leading Indian pharmaceutical company specializing in the development and manufacturing of high-quality biopharmaceuticals and specialty pharmaceuticals. With a strong focus on innovation and research, Gufic caters to healthcare providers, hospitals, and patients across various therapeutic segments. The company is committed to enhancing healthcare outcomes through its diverse product portfolio and strategic partnerships. Gufic's dedication to quality and compliance ensures that it meets the highest industry standards, making it a trusted name in the Indian pharmaceutical landscape.
- Established leader in biopharmaceuticals
- Focus on innovation and research
- Wide range of therapeutic products
- Strong commitment to quality and compliance
- Trusted by healthcare providers and patients
- Strategic partnerships enhance market reach
Investment Thesis
Gufic Biosciences Ltd presents a compelling investment opportunity due to its strong promoter credibility, significant growth potential in digital services, and attractive valuation compared to peers. The company's strategic positioning and robust fundamentals position it well for future growth.
- Promoter group with a proven track record enhances investor confidence.
- Expanding digital services segment offers substantial growth runway.
- Valuation remains attractive relative to industry peers, presenting a buying opportunity.
- Strong fundamentals support sustainable revenue growth and profitability.
- Commitment to innovation positions Gufic for long-term success.
Opportunity vs Risk
Opportunities
- Growing demand for biopharmaceuticals
- Expansion into international markets
- Strong R&D capabilities
- Strategic partnerships with healthcare firms
Risks ⚠️
- Regulatory changes impacting operations
- High competition in biotech sector
- Dependence on key products
- Market volatility affecting stock price
Peer Perspective
Gufic Biosciences Ltd trades at a premium compared to peers like Biocon and Sun Pharma, reflecting its strong growth potential; however, a sustained improvement in margin stability is crucial for further rerating.
Future Outlook
Gufic Biosciences Ltd is poised for growth, driven by expanding product lines and market presence; however, successful execution and stringent cost control will be crucial to fully capitalize on these opportunities.
AI FAQs for Retail Users
- Q: What does Gufic Biosciences Ltd do?A: Gufic Biosciences Ltd is involved in manufacturing and marketing pharmaceutical products and biotechnology.
- Q: Is Gufic Biosciences Ltd a profitable company?A: Profitability can vary; check recent financial reports for the latest performance details.
- Q: What are the risks of investing in Gufic Biosciences Ltd?A: Risks include market competition, regulatory changes, and fluctuations in demand for healthcare products.
- Q: How can I buy shares of Gufic Biosciences Ltd?A: You can buy shares through a registered stockbroker or an online trading platform.
- Q: What factors influence Gufic Biosciences Ltd's stock price?A: Stock price can be influenced by company performance, market trends, and economic conditions.
📊 Stock Investment Checklist (100 Points)
Gufic Biosciences Ltd • Updated: 2025-09-17 02:15:42
-
10BusinessHighThe sector is growing with increasing demand for biopharmaceuticals, but competition is high.
-
10GrowthHighConsistent revenue growth observed over the past few years, but profit margins are fluctuating.
-
10ProfitabilityHighROE and ROCE are decent, but cash flow is inconsistent compared to net profit.
-
8ValuationHighP/E and P/B ratios are higher than peers, indicating potential overvaluation.
-
7BalanceHighDebt levels are manageable, but liquidity ratios are on the lower side.
-
6GovernanceGoodPromoter holding is strong, but there are some concerns regarding pledging.
-
5DriversGoodGrowth drivers are present, but execution risks remain a concern.
-
5TechnicalsGoodMarket sentiment is mixed, with low liquidity affecting price action.
Final Score & Verdict
Score 68 / 100
• Decent
Gufic Biosciences Ltd shows potential for growth in a promising sector, but faces challenges in profitability and valuation metrics. Investors should proceed with caution.
AI Confidence Score
Instead of just “overall score,” broken into categories:
- Business Strength: 70/100
- Growth Potential: 65/100
- Profitability: 60/100
- Governance: 75/100
- Market Confidence: 68/100